Capricor Therapeutics (NASDAQ:CAPR) Receives Neutral Rating From B. Riley Financial

Capricor Therapeutics Investors Who Suffered Losses Are Encouraged to Contact Johnson Fistel

SAN DIEGO, July 27, 2026 (GLOBE NEWSWIRE) -- Johnson Fistel, PLLP is investigating whether Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ: CAPR) or certain of its officers and directors violated federal securities laws by misrepresenting or failing to timely…

FDA staff flags data concerns about Capricor's therapy; shares plunge

Capricor Therapeutics (NASDAQ:CAPR) Receives Neutral Rating from B. Riley Financial

B. Riley Financial restated a "neutral" rating and set a $10.00 target price on shares of Capricor Therapeutics in a research report on Monday.

FDA shares warning about stroke prevention device after injury

Customers should return these devices to the manufacturer, Boston Scientific, due to a risk of the tip separatng during use.

FDA scientists question Capricor data; Legend CEO steps down

Capricor shares lost much of their value ahead of a high-stakes advisory committee meeting. Elsewhere, Ying Huang’s resignation extended a stock slide for Legend and AstraZeneca disclosed more pipeline trouble.

Capricor plunges on FDA AdCom briefing doc for Duchenne treatment

Capricor plunges after FDA briefing questions deramiocel efficacy/safety ahead of July 29 panel. Read more here.